Feasibility and Preliminary Safety of Smartphone-Based Automated Insulin Delivery in Adolescents and Children With Type 1 Diabetes.
In: Journal of diabetes science and technology, Jg. 18 (2024-03-01), Heft 2, S. 363-371
Online
academicJournal
Zugriff:
Background: A smartphone-based automated insulin delivery (AID) controller device can facilitate use of interoperable components and acceptance in adolescents and children.
Methods: Pediatric participants (N = 20, 8F) with type 1 diabetes were enrolled in three sequential age-based cohorts: adolescents (12-<18 years, n = 8, 5F), school-age (8-<12 years, n = 7, 2F), and young children (2-<8 years, n = 5, 1F). Participants used the interoperable artificial pancreas system (iAPS) and zone model predictive control (MPC) on an unlocked smartphone for 48 hours, consumed unrestricted meals of their choice, and engaged in various unannounced exercises. Primary outcomes and stopping criteria were defined using fingerstick blood glucose (BG) data; secondary outcomes compared continuous glucose monitoring (CGM) data with preceding sensor augmented pump (SAP) therapy.
Results: During AID, there was no more than one BG <50 mg/dL except in one young child participant; no instance of more than two episodes of BG ≥300 mg/dL lasting longer than 2 hours; and no adverse events. Despite large meals (total of 404.9 grams of carbs) and unannounced exercise (total of 182 minutes), overall CGM percent time in range (TIR) of 70 to 180 mg/dL during AID was statistically similar to SAP (63.5% vs 57.3%, respectively, P = .145). Overnight glucose standard deviation was 43 mg/dL (vs SAP 57.9 mg/dL, P = .009) and coefficient of variation was 25.7% (vs SAP 34.9%, P < .001). The percent time in closed-loop mode and connected to the CGM was 92.7% and 99.6%, respectively. Surveys indicated that participants and parents/guardians were satisfied with the system.
Conclusions: The smartphone-based AID was feasible and safe in sequentially younger cohorts of adolescents and children.
Clinicaltrials.gov: NCT04255381 (https://clinicaltrials.gov/ct2/show/NCT04255381).
Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: S.A.W. has received honoraria for serving as a speaker for Abbott and Dexcom, has served as consultant for Zealand, and receives grant support from NIH and Abbott. L.M.N. receives grant support from the NIH and product support from Dexcom. L.M.L. participates in consulting and on advisory boards for Medtronic, Insulet, Dexcom, Roche, Janssen, Boehringer Ingelheim, Eli Lilly, Provention, and Dompe, and receives grant support from NIH, JDRF, and Helmsley Charitable Trust. F.J.D. reports equity, licensed IP and is a member of the Scientific Advisory Board of Mode AGC. E.D. reports receiving grants from JDRF, NIH, and Helmsley Charitable Trust, personal fees from Roche and Eli Lilly, patents on artificial pancreas technology, and product support from Dexcom, Insulet, Tandem, and Roche. E.D. is currently an employee and shareholder of Eli Lilly and Company. The work presented in this manuscript was performed as part of his academic appointment and is independent of his employment with Eli Lilly and Company. All other authors report no conflict of interest related to this article.
Titel: |
Feasibility and Preliminary Safety of Smartphone-Based Automated Insulin Delivery in Adolescents and Children With Type 1 Diabetes.
|
---|---|
Autor/in / Beteiligte Person: | Deshpande, S ; Weinzimer, SA ; Gibbons, K ; Nally, LM ; Weyman, K ; Carria, L ; Zgorski, M ; Laffel, LM ; Doyle FJ 3rd ; Dassau, E |
Link: | |
Zeitschrift: | Journal of diabetes science and technology, Jg. 18 (2024-03-01), Heft 2, S. 363-371 |
Veröffentlichung: | 2014- : Thousand Oaks, CA : Sage ; <i>Original Publication</i>: Foster City, CA : Diabetes Technology Society, 2024 |
Medientyp: | academicJournal |
ISSN: | 1932-2968 (electronic) |
DOI: | 10.1177/19322968221116384 |
Schlagwort: |
|
Sonstiges: |
|